News

During Heart Month, we are talking about atrial fibrillation, the recent changes in guidelines, and how Saint Luke’s is leading the way in innovative treatments for those who have a-fib.

Saint Luke’s Mid America Heart Institute was the first in Kansas and Missouri, and one of only 27 US institutions, to participate in PULSED AF clinical trial.

The groundbreaking STEP-HFpEF study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named one of the top advances by the American Heart Association.

We are talking about lung cancer and how precision oncology helps patients diagnosed with the disease with treatment.

TAVR in asymptomatic and minimally symptomatic patients is associated with a high survival rate, but relatively minor improvements, according to new research.

Dr. Tim Pluard, medical director of Saint Luke’s Koontz Center for Advanced Breast Cancer and of Saint Luke’s Cancer Institute, talks about innovative treatment options for breast cancer and clinical trials offered at Saint Luke’s.

We’re talking about how younger women and men can monitor for breast cancer and recent updates in screening guidelines.

This week during Breast Cancer Awareness Month, we’re talking about metastatic breast cancer and Saint Luke’s Koontz Center—the region’s only center dedicated and designed specifically for these patients.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.